Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-induced diabetic rats

International Journal of Molecular Sciences

Volumn 15, Issue 2, 2014, Pages 2015-2023

  Alkaladi, Ali ^a   Abdelazim, Aaser Mohamed ^b   Afifi, Mohamed ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Zagazig University   (Egypt)

Author keywords

Diabetes; SNPs; ZnONPs

Indexed keywords

GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; INSULIN RECEPTOR; NANOPARTICLE; SILVER NANOPARTICLE; STREPTOZOCIN; UNCLASSIFIED DRUG; ZINC OXIDE NANOPARTICLE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; METAL NANOPARTICLE; SILVER; ZINC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; INSULIN RELEASE; MALE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BLOOD; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS ISLET; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION; GLUCOKINASE; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; METAL NANOPARTICLES; RATS; SILVER; ZINC OXIDE;

EID: 84893200808     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15022015     Document Type: Article

References (27)

1. Lin, Y.; Sun, Z. Current views on Type 2 diabetes. J. Endocrinol. 2010, 204, 1-11.
2. Thompson, K.H.; Lichter, J.; LeBel, C.; Scaife, M.C.; McNeill, J.H.; Orvig, C. Vanadium treatment of Type 2 diabetes: A view to the future. J. Inorg. Biochem. 2009, 103, 554-558.
3. Wang, Z.Q.; Cefalu, W.T. Current concepts about chromium supplementation in Type 2 diabetes and insulin resistance. Curr. Diabetes Rep. 2010, 10, 145-151.
4. Wells, I.C. Evidence that the etiology of the syndrome containing Type 2 diabetes mellitus results from abnormal magnesium metabolism. Can. J. Physiol. Pharmacol. 2008, 86, 16-24.
5. Chausmer, A.B. Zinc, insulin and diabetes. J. Am. Coll. Nutr. 1998, 17, 109-115.
6. Haase, H.; Overbeck, S.; Rink, L. Zinc supplementation for the treatment or prevention of disease: Current status and future perspectives. Exp. Gerontol. 2008, 43, 394-408.
7. Jansen, J.; Karges, W.; Rink, L. Zinc and diabetes-Clinical links and molecular mechanisms. J. Nutr. Biochem. 2009, 20, 399-417.
8. Sun, Q.; van Dam, R.M.; Willett, W.C.; Hu, F.B. Prospective study of zinc intake and risk of Type 2 diabetes in women. Diabetes Care 2009, 32, 629-634.
9. Smidt, K.; Jessen N.; Petersen, A.B. SLC30A3 responds to glucose-and zinc variations in b-cells and is critical for insulin production and in vivo glucose-metabolism during b-cell stress. PLoS One 2009, 4, e5684-e5691.
10. Rungby, J. Zinc, zinc transporters and diabetes. Diabetologia 2010, 53, 1549-1551.
11. Ukperoro, J.U.; Offiah, N.; Idris, T.; Awogoke, D. Antioxidant effect of zinc, selenium and their combination on the liver and kidney of alloxan-induced diabetes in rats. Med. J. Nutr. Metab. 2010, 3, 25-30.
12. Yih, T.C.; Al-Fandi, M.J. Engineered nanoparticles as precise drug delivery system. J. Cell. Biochem. 2006, 97, 1184-1190.
13. Hirst, S.M.; Karakoti, A.S.; Tyler, R.D.; Sriranganathan, N.; Seal, S.; Reilly, C.M. Anti-inflammatory properties of cerium oxide nanoparticles. Small 2009, 5, 2848-2856.
14. Richards-Williams, C.; Contreras, J.L.; Berecek, K.H.; Schwiebert, E.M. Extracellular ATP and zinc are co-secreted with insulin and activate multiple P2X purinergic receptor channels expressed by islet β-cells to potentiate insulin secretion. Purinergic Signal. 2008, 4, 393-405.
15. Umrani, D.R.; Paknikar, K.M. Zinc oxide nanoparticles show antidiabetic activity in streptozotocin-induced Types 1 and 2 diabetic rats. Nanomedicine 2014, 9, 89-104.
16. Wijesekara, N.; Dai, F.F.; Hardy, A.B. Beta cell-specific ZnT8 deletion in mice causes marked defects in insulin processing, crystallization and secretion. Diabetologia 2010, 53, 1656-1658.
17. Mocchegiani, E.; Giacconi, R.; Malavolta, M. Zinc signalling and subcellular distribution: Emerging targets in Type 2 diabetes. Trends Mol. Med. 2008, 14, 419-428.
18. White, M.F.; Yenush, L. The IRS-signaling system: A network of docking proteins that mediate insulin and cytokine action. Curr. Top. Microbiol. Immunol. 1998, 228, 179-208.
19. Matschinsky, F.M.; Magnuson, M.A.; Zelent, D.; Jetton, T.L.; Doliba, N.; Han, Y.; Taub, R.; Grimsby, J. The network of Glucokinase-expressing cells in glucose homeostasis and the potential of Glucokinase activators for diabetes therapy. Diabetes 2006, 55, 1-12.
20. Zhang, X.; Wenbo, L.; Yiqing, M.; Hui, L.; Yang, Y.; Huanran, T. Hepatic glucokinase activity is the primary defect in alloxan-induced diabetes of mice. Biomed. Pharmacother. 2009, 63, 180-186.
21. Tahrani, A.; Milan, K.; Amy, K.; Anthony, H. Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacol. Ther. 2010, 12, 328-361.
22. Van, S.E.; Veiga-da-Cunha, M.; Niculescu, L. The regulatory protein of glucokinase. Biochem. Soc. Trans. 1997, 25, 136-140.
23. Orci, L.; Unger, R.H.; Ravazzola, M. Reduced β-cell glucose transporter in new onset diabetic BB rats. J. Clin. Invest. 1990, 86, 1615-1622.
24. Brown, G.K. Glucose transporters: Structure, function and consequences of deficiency. J. Inherit. Metab. Dis. 2000, 23, 237-246.
25. Lee, K.N.; In, C.J.; Song, J.L.; Sang, H.O.; Moo, Y.C. Regulation of leptin gene expression by insulin and growth hormone in mouse adipocytes. Exp. Mol. Med. 2001, 33, 234-239.
26. Pakoskey, A.M.; Lesher, E.C.; Scott, D.B. Hexokinase of Escherichia coli. assay of enzyme activity and adaptation to growth in various media. J. Gen. Microbiol. 1965, 38, 73-80.
27. Bancroft, J.D.; Gamble, M. Theory and Practice of Histological Technique, 4th Ed.; Churchill: Livingston, NY, USA, 2008.